antibody αpd1  (Bio X Cell)

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: BsAb αPD1+αPDL1 simultaneously binds PD1 on the tumor cell and PDL1 on the CD8 + T cell, engaging both cell types together while reinvigorating the CD8 + T cells, further contributing to tumor cell death.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques:

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: Synthesis and characterization of BsAb αPD1+αPDL1 . (A) Schematic representation and preparation of BsAb αPD1+αPDL1 . (B) Transmission electron microscopy (TEM) images of BsAb αPD1+αPDL1 (Scale bar: 1 μm). (C) Molecular weight of αPD1, αPDL1 and BsAb αPD1+αPDL1 , as measured by asymmetric flow field-flow fractionation coupled with multiangle laser light scattering. (D) Particle size of PGLU-Fc-III-4C and BsAb αPD1+αPDL1 , as detected by DLS. Average diameters for each sample are shown. (E) The molecular weights of PGLU, PGLU-Fc-III-4C, BsAb αPD1+αPDL1 were measured with Gel Permeation Chromatography (GPC). (F) Flow cytometric analysis detecting FITC labeled anti-PD1 and PE-Cy7 labeled anti-PDL1 antibodies conjugated into a BsAb αPD1+αPDL1 .

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Transmission Assay, Electron Microscopy, Molecular Weight, Field Flow Fractionation, GPC Assay, Labeling

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: In vitro stability testing, tumor inhibition and CD8 + T cell activation activity of BsAb αPD1+αPDL1 . (A) Schematic representation of the experimental of stability testing. (B) Flow cytometry analysis detecting the stimulative stability of PGLU-Fc-III-4C-hIgG-PE-Cy7 in human blood in 72 h, in which the hIgG was 9.5 g/L. PGLU-Fc-III-4C without hIgG-PE-Cy7 was used as a control for gating. (C) Schematic representation of the experimental process assessing in vitro activity of BsAb αPD1+αPDL1 in a co-culture of MC38 cells and CD8 + T cells. (D–F) IFN-γ, perforin, and granzyme B ELISA results from supernatants of co-cultured MC38 cells and CD8 + T cells at 24 h after treatment. (G) CCK-8 assay detecting different drugs induced anti-tumor effect of CD8 + T cells.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: In Vitro, Inhibition, Activation Assay, Activity Assay, Flow Cytometry, Control, Co-Culture Assay, Enzyme-linked Immunosorbent Assay, Cell Culture, CCK-8 Assay

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: (A) Optical microscope photographs of the cocultured MC38 and CD8 + T cells at 6 h after treatment with PBS, NP αPD1 +NP αPD1 and BsAb αPD1+αPDL1. In vivo biodistribution of Cy5-labeled NP αPD1 +NP αPD1 and BsAb αPD1+αPDL1. (B) In vivo fluorescent imaging of drug distribution in mice at 4 h and 24 h post-injection and quantitative analysis of the fluorescence in the tumor (n = 3 mice/group).

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Microscopy, In Vivo, Labeling, Imaging, Injection, Fluorescence

Journal: Materials Today Bio

Article Title: Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy

doi: 10.1016/j.mtbio.2024.101239

Figure Lengend Snippet: H&E staining of tumors (Scale bar: 400 μm) and representative immunofluorescence images of tumors (Scale bar: 500 μm) after BsAb αPD1+αPDL1 treatment.

Article Snippet: Anti-mouse PD1 antibody (αPD1, Rat IgG1, κ; Catalog: BE0146), anti-mouse PDL1 antibody (αPDL1, Rat IgG2b, κ; Catalog: BE0101) were procured from Bio X Cell (West Lebanon, NH, USA).

Techniques: Staining, Immunofluorescence

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8 + -T cell immunity.

doi: 10.1186/s13046-023-02686-1

Figure Lengend Snippet: Fig. 6 RT/TMZ/PL reshapes immunosuppressive microenvironment to induce CD3+/CD4+/CD8+ T cells infiltration in G422TN-tumors. A Immune cell pro portion analysis in each sample. B and C The line chart illustrating CD 8 T cell and CD 4 T cell proportion in different treatments. D The heatmap illustrating expression of marker genes involved in Hypoxic TAMs, IFN TAMs, lipid TAMs and transitory TAMs in different treatments. E ssGSEA score of TAMs subtypes in different treatments. F and G Expressions of PD1 and PD-L1 in different treatments. H, I, J and K IHC staining (CD3, CD4, CD8 and Foxp3) and statistical analysis of G422TN-tumor in control, PL, RT/TMZ, RT/TMZ/PL, RT/TMZ/PL/GSH group on day 9 p.i. Scale bar, 50 μm. (n = 6). L and M Flow cytometric analysis of T cell gating and statistical analysis in spleen of mice of different groups (control, RT/TMZ and RT/TMZ/PL, n = 3–5). (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not statistically significant)

Article Snippet: Piperlongumine, glutathione, mannose and anti-PD-1 antibody (αPD1) treatment Piperlongumine (Selleck Chemicals, China) was dissolved in tween-80/water (10/90, v/v) at a final concentration of 0.5 mg/ml, and was administered to mice (5 mg/ kg/d) daily via intraperitoneal injection according to corresponding therapeutic schedules.

Techniques: Expressing, Marker, Immunohistochemistry, Control

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8 + -T cell immunity.

doi: 10.1186/s13046-023-02686-1

Figure Lengend Snippet: Fig. 7 αPD1 synergizes RT/TMZ/PL but not RT/TMZ to achieve substantial immune cure in G422TN-mice. A Schematic diagram depicting the PL, RT, TMZ, αPD1, or their combined regimen started on day 7 p.i. αPD1, 6 doses of αPD1 with once oral gavage of 200 µg/mouse except for first dose (400 µg/ mouse). B and C The Kaplan-Meier survivals and body weight changes of the G422TN-mice with PL, TR, TMZ, αPD1, or their combined regimen started on day 7 p.i. (n = 8/group). D and E Representative bioluminescent images and the Kaplan-Meier survivals of control (n = 7), RT/TMZ/PL/αPD1 (LTS, n = 4), RT/ TMZ/αPD1 (LTS, n = 1) and RT/TMZ/PL (LTS, n = 1) group during rechallenge. (*P < 0.05; ns, not statistically significant)

Article Snippet: Piperlongumine, glutathione, mannose and anti-PD-1 antibody (αPD1) treatment Piperlongumine (Selleck Chemicals, China) was dissolved in tween-80/water (10/90, v/v) at a final concentration of 0.5 mg/ml, and was administered to mice (5 mg/ kg/d) daily via intraperitoneal injection according to corresponding therapeutic schedules.

Techniques: Control